NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Shift Bioscience

Shift Bioscience

Private
CambridgeHealthcare & Life Scienceshttps://shiftbioscience.com/

Last Round

Seed

Oct 15, 2024

Total Funding Raised

$20M

Company Overview

Shift Bioscience is a biotechnology company that develops cell rejuvenation therapies for age-related diseases using an AI-driven cell simulation platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Medical AI, Healthcare Analytics

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

cellular rejuvenationlongevity biotechdrug discoveryrejuvenationAI drug discoveryepigenetic reprogramminglongevityregenerative medicineanti-aging therapeuticslongevity sciencegene therapybiotech platformage-related diseasebio-ai

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Shift Bioscience Comparables

Compare Shift Bioscience with similar companies based on industry and business-model similarity.

Shift Bioscience comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Clock.bio
90%
Gero
84%
Turn Biotechnologies
80%

Shift Bioscience Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedOct 15, 2024
Pre SeedJul 21, 2021

Key People

Founding team and executive leadership

Daniel Ives

CEO And Founder

Founding Team

Andrew Armour

Chief Financial Officer

Executive Team

Shift Bioscience Investors

Notable investors and investment history

Shift Bioscience investors
InvestorRounds
BGFSeed
F-Prime CapitalSeed
Kindred CapitalPre Seed, Seed
F-Prime CapitalPre Seed, Seed
Healthspan CapitalPre Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 13, 2025

    Developing a platform to identify cell-rejuvenating transcription factor combinations.

  • May 20, 2025

    Sir Tony Kouzarides appointed as Scientific Advisor.

Shift Bioscience Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Shift Bioscience Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Shift Bioscience's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge
Employee Range24
Year Founded2017
Last FundingOct 15, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.